Sympathetic improvement of cancer vaccine efficacy

References

• Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939–44. doi:10.1038/nm1447.
   PubMed Web of Science ®Google Scholar
• Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol. 2008;5(8):466–75. doi:10.1038/ncponc1134.
   PubMedGoogle Scholar
• Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, et al. Stress effects on fosb- and interleukin-8 (il8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010;285(46):35462–70. doi:10.1074/jbc.M110.109579.
   PubMed Web of Science ®Google Scholar
• Chung JF, Lee SJ, Sood AK. Immunological and pleiotropic effects of individual beta-blockers and their relevance in cancer therapies. Expert Opin Investig Drugs. 2016;25(5):501–05. doi:10.1517/13543784.2016.1164141.
   PubMed Web of Science ®Google Scholar
• Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: A population- based study. J Clin Oncol. 2011;29(19):2635–44. doi:10.1200/JCO.2010.33.5422.
   PubMed Web of Science ®Google Scholar
• Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628–38. doi:10.18632/oncotarget.v1i7.
   PubMed Web of Science ®Google Scholar
• Kanemi O, Zhang X, Sakamoto Y, Ebina M, Nagatomi R. Acute stress reduces intraparenchymal lung natural killer cells via beta-adrenergic stimulation. Clin Exp Immunol. 2005;139(1):25–34. doi:10.1111/cei.2005.139.issue-1.
   PubMed Web of Science ®Google Scholar
• Poirier L, Tobe SW. Contemporary use of beta-blockers: clinical relevance of subclassification. Can J Cardiol. 2014;30(5 Suppl):S9–S15. doi:10.1016/j.cjca.2013.12.001.
   PubMed Web of Science ®Google Scholar
• Brooks AM, Gillies WE. Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging. 1992;2(3):208–21. doi:10.2165/00002512-199202030-00005.
   PubMed Web of Science ®Google Scholar
• Singh BN, Whitlock RM, Comber RH, Williams FH, Harris EA. Effects of cardioselective beta adrenoceptor blockade on specific airways resistance in normal subjects and in patients with bronchial asthma. Clin Pharmacol Ther. 1976;19:493–501.
   PubMed Web of Science ®Google Scholar
• Frohlich ED, Tarazi RC, Dustan HP. Peripheral arterial insufficiency. A complication of beta-adrenergic blocking therapy. JAMA. 1969;208(13):2471–72. doi:10.1001/jama.1969.03160130055016.
   PubMed Web of Science ®Google Scholar
• Antonis A, Clark ML, Hodge RL, Molony M, Pilkington TR. Receptor mechanisms in the hyperglycaemic response to adrenaline in man. Lancet. 1967;1(7500):1135–37. doi:10.1016/S0140-6736(67)91710-2.
   PubMed Web of Science ®Google Scholar
• Lim M, Linton RA, Wolff CB, Band DM. Propranolol, exercise, and arterial plasma potassium. Lancet. 1981;2(8246):591. doi:10.1016/S0140-6736(81)90987-9.
   PubMed Web of Science ®Google Scholar
• Nowicki M, Miszczak-Kuban J. Nonselective beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients. Nephron. 2002;91(2):222–27. doi:10.1159/000058396.
   PubMed Web of Science ®Google Scholar
• Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351–57. doi:10.1001/jama.288.3.351.
   PubMed Web of Science ®Google Scholar
• Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, Liu H, Kokolus KM, Eng JW, Messmer MN, et al. Beta-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in cd8(+) t cells and undermines checkpoint inhibitor therapy. Cancer Res. 2017;77(20):5639–51. doi:10.1158/0008-5472.CAN-17-0546.
   PubMed Web of Science ®Google Scholar
• Daher C, Vimeux L, Stoeva R, Peranzoni E, Bismuth G, Wieduwild E, Lucas B, Donnadieu E, Bercovici N, Trautmann A, et al. Blockade of β-Adrenergic receptors improves CD8+T-cell priming and cancer vaccine efficacy. Cancer Immunol Res. 2019;7(11):1849–63. doi:10.1158/2326-6066.CIR-18-0833.
   Web of Science ®Google Scholar
• Scanzano A, Cosentino M. Adrenergic regulation of innate immunity: A review. Front Pharmacol. 2015;6:171.
   PubMed Web of Science ®Google Scholar
• Panina-Bordignon P, Mazzeo D, Lucia PD, D’Ambrosio D, Lang R, Fabbri L, Self C, Sinigaglia F. Beta2-agonists prevent th1 development by selective inhibition of interleukin 12. J Clin Invest. 1997;100(6):1513–19. doi:10.1172/JCI119674.
   PubMed Web of Science ®Google Scholar
• Sloan EK, Capitanio JP, Cole SW. Stress-induced remodeling of lymphoid innervation. Brain Behav Immun. 2008;22(1):15–21. doi:10.1016/j.bbi.2007.06.011.
   PubMed Web of Science ®Google Scholar
• Treinys R, Bogdelis A, Rimkute L, Jurevicius J, Skeberdis VA. Differences in the control of basal l-type ca(2+) current by the cyclic amp signaling cascade in frog, rat, and human cardiac myocytes. J Physiol Sci. 2016;66(4):327–36. doi:10.1007/s12576-015-0430-3.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li X, Yang L, Eckel-Mahan K, Tong Q, Gu X, Kolonin MG, Sun K. Transient overexpression of vascular endothelial growth factor a in adipose tissue promotes energy expenditure via activation of the sympathetic nervous system. Mol Cell Biol. 2018;38(22). doi:10.1128/MCB.00242-18.
   Web of Science ®Google Scholar
• Shusterman V, Usiene I, Harrigal C, Lee JS, Kubota T, Feldman AM, London B. Strain-specific patterns of autonomic nervous system activity and heart failure susceptibility in mice. Am J Physiol Heart Circ Physiol. 2002;282(6):H2076–2083. doi:10.1152/ajpheart.00917.2001.
   PubMed Web of Science ®Google Scholar
• Estrada LD, Agac D, Farrar JD. Sympathetic neural signaling via the beta2-adrenergic receptor suppresses t-cell receptor-mediated human and mouse cd8(+) t-cell effector function. Eur J Immunol. 2016;46(8):1948–58. doi:10.1002/eji.201646395.
   PubMed Web of Science ®Google Scholar
• Qiao G, Bucsek MJ, Winder NM, Chen M, Giridharan T, Olejniczak SH, Hylander BL, Repasky EA. Beta-adrenergic signaling blocks murine cd8(+) t-cell metabolic reprogramming during activation: A mechanism for immunosuppression by adrenergic stress. Cancer Immunol Immunother. 2019;68(1):11–22. doi:10.1007/s00262-018-2243-8.
   PubMed Web of Science ®Google Scholar
• Ramer-Quinn DS, Baker RA, Sanders VM. Activated t helper 1 and t helper 2 cells differentially express the beta-2-adrenergic receptor: A mechanism for selective modulation of t helper 1 cell cytokine production. J Immunol. 1997;159:4857–67.
   PubMed Web of Science ®Google Scholar
• Carvajal Gonczi CM, Tabatabaei Shafiei M, East A, Martire E, Maurice-Ventouris MHI, Darlington PJ. Reciprocal modulation of helper th1 and th17 cells by the beta2-adrenergic receptor agonist drug terbutaline. Febs J. 2017;284(18):3018–28. doi:10.1111/febs.14166.
   PubMed Web of Science ®Google Scholar